Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma

Yoshinori Hoshino, Hirotoshi Hasegawa, Yoshiyuki Ishii, Takashi Endo, Hiroki Ochiai, Koji Okabayashi, Gou Kaneko, Shuji Mikami, Makio Mukai, Mototsugu Oya, Yuukou Kitagawa

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.

Original languageEnglish
Pages (from-to)412-416
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume17
Issue number4
DOIs
Publication statusPublished - 2012 Aug

Fingerprint

Renal Cell Carcinoma
Therapeutics
Emergencies
Intestinal Perforation
sunitinib
Peritonitis
Protein-Tyrosine Kinases
Laparotomy
Fatigue
Diarrhea
Neoplasms
Mucous Membrane
Clinical Trials
Carcinoma

Keywords

  • Emergency surgery
  • Perforation
  • Renal cell carcinoma
  • Sunitinib

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. / Hoshino, Yoshinori; Hasegawa, Hirotoshi; Ishii, Yoshiyuki; Endo, Takashi; Ochiai, Hiroki; Okabayashi, Koji; Kaneko, Gou; Mikami, Shuji; Mukai, Makio; Oya, Mototsugu; Kitagawa, Yuukou.

In: International Journal of Clinical Oncology, Vol. 17, No. 4, 08.2012, p. 412-416.

Research output: Contribution to journalArticle

Hoshino, Yoshinori ; Hasegawa, Hirotoshi ; Ishii, Yoshiyuki ; Endo, Takashi ; Ochiai, Hiroki ; Okabayashi, Koji ; Kaneko, Gou ; Mikami, Shuji ; Mukai, Makio ; Oya, Mototsugu ; Kitagawa, Yuukou. / Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma. In: International Journal of Clinical Oncology. 2012 ; Vol. 17, No. 4. pp. 412-416.
@article{9cce1d0cc8e947a285e0108e33f35b5b,
title = "Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma",
abstract = "Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.",
keywords = "Emergency surgery, Perforation, Renal cell carcinoma, Sunitinib",
author = "Yoshinori Hoshino and Hirotoshi Hasegawa and Yoshiyuki Ishii and Takashi Endo and Hiroki Ochiai and Koji Okabayashi and Gou Kaneko and Shuji Mikami and Makio Mukai and Mototsugu Oya and Yuukou Kitagawa",
year = "2012",
month = "8",
doi = "10.1007/s10147-011-0318-z",
language = "English",
volume = "17",
pages = "412--416",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Two cases of bowel perforation associated with sunitinib treatment for renal cell carcinoma

AU - Hoshino, Yoshinori

AU - Hasegawa, Hirotoshi

AU - Ishii, Yoshiyuki

AU - Endo, Takashi

AU - Ochiai, Hiroki

AU - Okabayashi, Koji

AU - Kaneko, Gou

AU - Mikami, Shuji

AU - Mukai, Makio

AU - Oya, Mototsugu

AU - Kitagawa, Yuukou

PY - 2012/8

Y1 - 2012/8

N2 - Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.

AB - Sunitinib, a multitargeted tyrosine kinase inhibitor, is widely used in the treatment of carcinoma. Adverse events associated with this treatment, including fatigue, diarrhea, and hematotoxicity, have been reported in clinical trials.Bowel perforation is a surgical emergency that requires immediate treatment depending on the location and progression of the tumor. We report 2 cases of bowel perforation during sunitinib treatment. The patients presented with diffuse peritonitis, and emergency exploratory laparotomy was performed. We speculate that the underlying mechanisms were decrease in capillary density of the normal mucosa in case 1 and tumor shrinkage because of sunitinib treatment in case 2. To the best of our knowledge, this is the first study to report the pathological findings implicating bowel perforation due to sunitinib treatment. Further investigations are needed to clarify the risk factors for intestinal perforations associated with sunitinib treatment.

KW - Emergency surgery

KW - Perforation

KW - Renal cell carcinoma

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=84867332744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867332744&partnerID=8YFLogxK

U2 - 10.1007/s10147-011-0318-z

DO - 10.1007/s10147-011-0318-z

M3 - Article

C2 - 21927829

AN - SCOPUS:84867332744

VL - 17

SP - 412

EP - 416

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 4

ER -